Summary of Key Points
China's innovative pharmaceutical industry is shifting from a "fast-follow" approach to one of "differentiating innovation," while facing challenges such as intense competition, decisions regarding internationalization strategies, the implementation of AI in drug development, and the need to restore sector valuations. Industry experts believe that by focusing on unmet patient needs, conducting differentiated research and development, pursuing diversified internationalization, and leveraging AI, the industry has a promising long-term outlook, with the sector expected to experience upward fluctuations in the future.
1. Innovation in Pharmaceuticals: Moving Beyond Copycatting
In the past, many pharmaceutical companies adopted a "fast-follow" strategy—imitating new drugs launched by others to minimize risks. However, when everyone did this, intense competition arose (for example, a surplus of drugs targeting the same therapeutic targets). To overcome this, experts suggest four approaches:
1. Targeting unexplored areas: Areas with high demand and low competition, such as central nervous system disorders, drug-resistant infections, and pediatrics.
2. Using the same molecule for multiple diseases: Forcing a molecule to treat different conditions can create unique value; for instance, using it to treat lung cancer instead of just gastric cancer.
3. Exploring new therapeutic targets: Choosing targets that have not been fully researched or are controversial, which carry higher initial risks but can lead to market dominance if successful.
4. Building technical platforms: Investing in cutting-edge technologies like ADC (antibody-drug conjugates), mRNA, and gene editing, which enable rapid development of new drugs. In short, before initiating a project, ask yourself: "Will my drug make life easier for patients or provide better treatment outcomes compared to existing ones?" Simply copying others is not enough; innovation requires finding new solutions.
2. Internationalization: A Necessary Path for Chinese Pharmaceutical Companies
To grow, Chinese companies must expand internationally. The approach to internationalization has evolved, shifting from selling individual drugs to entering into partnerships, joint research and development, or even establishing new companies abroad. Some view asset licensing (BD transactions) as a temporary strategy that involves selling early-stage research pipelines for immediate cash gains, though it may result in losses in the long run. However, experts argue that this is a necessary step:
- Small companies lack the funds for global clinical trials, and without selling these assets, their research may fail; selling them allows them to sustain operations.
- Larger companies can learn from international partners and also conduct their own Phase III trials, ultimately aiming to establish their own overseas sales networks. In the future, BD transactions are expected to stabilize, as multinational pharmaceutical companies are slowing down their acquisitions of Chinese assets, and domestic companies are becoming more financially capable to pursue international initiatives on their own.
3. AI in Pharmaceutical Development: Not a Magic Solution, but a Critical Tool
AI has gained prominence in drug development, but it is not a panacea:
- Current capabilities: AI helps in target identification, molecule design, and trial optimization, mainly reducing the time required for early-stage research. However, it still cannot significantly lower the costs of Phase II and III trials (e.g., patient recruitment and hospital expenses).
- Challenges: The lack of high-quality, accessible clinical data, the time-consuming validation process (3-5 years to prove the effectiveness of AI-designed molecules), and the lack of clear regulatory guidelines for AI-driven drugs.
- Future focus: The key will be on companies' own expertise and decision-making abilities, such as selecting appropriate targets and designing effective clinical trials. AI will not replace human expertise; it will merely accelerate the research process. Companies with extensive data and clinical experience will have a competitive advantage.
4. The Biopharmaceutical Sector: Currently Low, but with Potential for Growth?
The sector has risen by 6.94% since July but has recently corrected. Experts believe that valuations are still low and are expected to improve in the future:
- Supporting factors: Increased corporate share repurchases (indicating confidence in the industry's future), promising clinical data in the second half of the year, the growing demand due to an aging population, and healthcare policies that favor innovative drugs.
- Long-term trends: China's R&D costs for innovative drugs are half those of Europe and the U.S., providing opportunities for greater market expansion. Leading companies are expected to become profitable. Short-term fluctuations are not a concern; the sector is likely to show a steady upward trend over the long term.
Conclusion
China's innovative pharmaceutical industry is at a critical juncture of transformation. Despite challenges such as competition, funding issues, and regulatory hurdles, the industry holds significant potential for growth through differentiated innovation, internationalization, and the use of AI. Investors should focus on companies with core technologies, international presence, and efficient R&D capabilities.